caa a22 4500 465735118 CHVBK 20180323111752.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00167065 doi (NATIONALLICENCE)springer-10.1007/BF00167065 A pilot study of recombinant interferon beta (IFN-βser) in patients with recurrent glioma [Elektronische Daten] [W. Yung, A. Castellanos, P. Van Tassel, R. Moser, S. Marcus] Recombinant interferon beta (IFN-βser) has been administered by intravenous bolus injection three times weekly at a dose of 90 × 106 IU to 14, patients with recurrent malignant glioma in an ongoing study. The treatment period has ranged from 1 to 40 weeks. The most common adverse experiences were fever, chills, malaise, and headache. Fever, chills and headache were worse with the first two doses and were usually relieved with acetaminophen. All patients tolerated subsequent treatments without any difficulties. No neurologic or hematologic toxicities were observed. Of ten evaluable patients, five had progressive disease in 4 to 8 weeks; three had stable disease for 12 to 21 weeks; one has had a minor response for 13 weeks; and one has had a complete resolution of tumor for 150 + weeks. IFN-βser appears to have activity in human glioma and is well tolerated at this dosage and schedule. Kluwer Academic Publishers, 1990 malignant glioma nationallicence recurrent nationallicence chemotherapy nationallicence interferon nationallicence Yung W. Department of Neuro-Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, USA aut Castellanos A. Department of Neuro-Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, USA aut Van Tassel P. Department of Diagnostic Radiology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, USA aut Moser R. Department of Neurosurgery, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, USA aut Marcus S. Triton Biosciences Inc., 1501 Harbor Bay Parkway, 94501, Alameda, CA, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 9/1(1990-08-01), 29-34 0167-594X 9:1<29 1990 9 11060 https://doi.org/10.1007/BF00167065 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00167065 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yung W. Department of Neuro-Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Castellanos A. Department of Neuro-Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Van Tassel P. Department of Diagnostic Radiology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Moser R. Department of Neurosurgery, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Marcus S. Triton Biosciences Inc., 1501 Harbor Bay Parkway, 94501, Alameda, CA, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 9/1(1990-08-01), 29-34 0167-594X 9:1<29 1990 9 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer